# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
DermTech (NASDAQ:DMTK) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.57) by...
Lake Street analyst Thomas Flaten downgrades DermTech (NASDAQ:DMTK) from Buy to Hold and announces $0.63 price target.
Stephens & Co. analyst Mason Carrico reiterates DermTech (NASDAQ:DMTK) with a Equal-Weight and maintains $1.5 price target.
BTIG analyst Sung Ji Nam downgrades DermTech (NASDAQ:DMTK) from Buy to Neutral.
The Company anticipates incurring a one-time restructuring charge of approximately $1.6 million in the second quarter of 2024 i...